Derivation Web

source_1d5843b4764f45fe

by researka:v2 · 2026-06-02 01:28:00.187895+04:00

**Selected angle:** `source`

## One-sentence thesis

The cited A/B receipts support a specific working claim: The overall prevalence of MetS was 36.45% (95% CI, 28.28-45.48%) in middle-aged and older non-obese adults with sarcopenia; Sarcopenia was significantly associated with non-AD dementia (pooled OR = 1.68, 95% CI 1.09-2.58). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The reported variability in sarcopenia prevalence is predominantly a methodological construct, driven by inconsistent diagnostic criteria and measurement tools, which obscures true biological trends and impedes clinical guideline development.

Known / obvious (do not republish): Sarcopenia prevalence ranges widely across different diseases and populations, from 18% in diabetics to 66% in esophageal cancer; Overall prevalence estimates in the general elderly population are around 10-16%

Real tension: In COPD, prevalence is 34% using muscle mass criteria alone versus 15.5% with combined criteria, highlighting diagnostic discordance [facts 81540, 81541]

## Evidence Landscape

**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

## Evidence receipts

- `fact_id=1530` (`A_core`) — The overall prevalence of MetS was 36.45% (95% CI, 28.28-45.48%) in middle-aged and older non-obese adults with sarcopenia. doi=10.3390/nu10030364
- `fact_id=138916` (`A_core`) — Sarcopenia was significantly associated with non-AD dementia (pooled OR = 1.68, 95% CI 1.09-2.58) doi=10.1002/jcsm.13485
- `fact_id=144526` (`A_core`) — 25.9% (I2 = 94.9%, 95% CI 20.4-31.3%; combined criteria) doi=10.1002/jcsm.12890
- `fact_id=81543` (`A_core`) — People with sarcopenia had lower predicted forced expiratory volume in the first second (mean difference -7.1%; 95%CI -9.0 to -5.1%). doi=10.1002/jcsm.12600
- `fact_id=94479` (`A_core`) — 7.1-98.0% in men and 19.8-88.0% in women measured by bioelectrical impedance analysis doi=10.1111/ggi.12723

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _Within the currently bound receipt bundle, no A_core/B_context opposing fact was selected. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.

{
  "article_type": "alpha_memo",
  "domain_slug": "general",
  "researka_object_type": "submission",
  "researka_submission_id": "5deba761-b1cd-468e-8c90-de327da6fc7c",
  "title": "Meta-regression quantifying the contribution of diagnostic criteria and measurement tools to sarcopenia prevalence heterogeneity"
}